All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2024-03-25T16:56:36.000Z

GLOW trial: A 4-year update on fixed-duration ibrutinib + venetoclax in previously untreated CLL

Mar 25, 2024
Share:
Learning objective: After reading this article, learners will be able to recall key data from the phase III GLOW trial (NCT03462719) of ibrutinib plus venetoclax in patients with previously untreated chronic lymphocytic leukemia.

Bookmark this article

Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.

Bruton kinase inhibitors such as ibrutinib have significantly improved the treatment landscape of chronic lymphocytic leukemia (CLL). Ibrutinib and venetoclax, a B-cell lymphoma 2 inhibitor, are complementary in their mode of action; phase II studies have shown deep, durable responses, and improvements in progression-free survival (PFS), including in patients with high-risk CLL disease.

The Lymphoma Hub has previously reported findings from the GLOW trial. Here, we summarize a recently published article by Niemann et al.1 in The Lancet Oncology on the 4-year follow-up of the phase III GLOW trial (NCT03462719) investigating fixed duration ibrutinib + venetoclax vs chlorambucil + obinutuzumab in patients with previously untreated CLL.

Study design1

GLOW is a randomized, multicenter study conducted across 14 countries in patients with previously untreated CLL. Eligible patients were aged ≥65 years or 18–64 years with comorbidities (cumulative illness rating scale score of >6/creatinine clearance of <70 mL/min), or both and had an Eastern Cooperative Oncology Group performance status of ≤2. Patients were randomized as shown in Figure 1.

The primary endpoint was PFS assessed by an independent review committee, defined as the time from randomization until disease progression or death from any cause.

Secondary endpoints included:

  • Measurable residual disease (MRD) negativity rate: the proportion of patients who had undetectable MRD in bone marrow
  • Complete response (CR) rate: number of patients who achieved CR or CR with incomplete bone marrow recovery (CRi)
  • Overall response rate: number of patients who achieved CR, CRi, or partial response
  • Overall survival (OS): time from randomization to death from any cause
  • Duration of CR: time from initial CR or CRi until disease progression or death from any cause
  • Time to next treatment: time from randomization until the start of any subsequent anticancer therapy and safety

Figure 1. Treatment schema* 

OD, once daily.
*Adapted from Niemann, et al.1

Results1

A total of 211 patients received ibrutinib + venetoclax (n = 106) and chlorambucil + obinutuzumab (n = 105). The baseline characteristics are summarized in Table 1.

Table 1. Baseline characteristics*

Characteristic, % (unless otherwise stated)

Ibrutinib + 

venetoclax arm
(n = 106)

Chlorambucil +
obinutuzumab arm
(n = 105)

Median age, years

71

71

Sex

 

 

              Male

55.7

60.0

ECOG PS 1−2

67.0

62.9

Median CIRS score, n

9

8

              >6

69.8

58.1

Median CrCL, mL/min

66.5

63.2

Rai stage III–IV

57.3

52.5

Bulky disease ≥5 cm

39.0

36.2

Elevated LDH

33.0

48.6

IGHV status

 

 

              Mutated

30.2

33.3

              Unmutated

63.2

54.3

              Unknown

6.6

12.4

Del(11q)

18.9

17.1

TP53 mutation

6.6

1.9

CIRS, cumulative illness rating scale; CrCL, creatinine clearance; ECOG PS, Eastern Cooperative Oncology Group performance status; IGHV, immunoglobulin heavy chain variable region gene; IQR, interquartile range; LDH, lactate dehydrogenase.
*Data from Niemann, et al.1
Denotes >10% numerical difference between arms.
IGHV status of baseline samples were updated since primary analysis based on post hoc reclassification using clonoSEQ. 35 out of 48 patient samples that were classified as unknown by Sanger sequencing during the primary analysis were reclassified using clonoSEQ and in the remaining 13, reclassification was not possible.

Efficacy

At a median follow-up of 46 months:

  • The PFS remained significantly higher in the ibrutinib + venetoclax arm vs chlorambucil + obinutuzumab arm, with 29 vs 78 events (p < 0·0001) reported in each arm, respectively (Figure 2).
    • The median PFS was not reached in the ibrutinib + venetoclax arm and was 21.7 months in the chlorambucil + obinutuzumab arm.
  • Univariate and multivariate analyses revealed a significant association between immunoglobulin heavy chain variable gene (IGHV) mutational status (mutated vs unmutated) and PFS in both treatment arms (p < 0.05).
  • In the ibrutinib + venetoclax arm, the 2-year PFS for patients with undetectable (n = 58) and detectable MRD (n = 31), 3 months posttreatment was 93% and 79.6%, respectively.
    • In patients with mutated IGHV, the 2-year PFS for those with detectable (n = 14) and undetectable MRD (n = 13), 3 months posttreatment was 92.3% and 100%, respectively.
    • In patients with unmutated IGHV, the 2-year PFS for those with detectable (n = 16) and undetectable MRD (n = 40), 3 months posttreatment was 67% and 89.9%, respectively.
  • In the chlorambucil + obinutuzumab arm, the 2-year PFS for patients with undetectable (n = 41) and detectable MRD (n = 47), 3 months posttreatment was 66.6% and 18%, respectively.
  • Post hoc analysis investigating MRD levels in the ibrutinib + venetoclax group by IGHV mutation status revealed that:
    • Undetectable MRD rates were higher in the unmutated IGHV subgroup (52% of 67 participants) vs the mutated IGHV subgroup (31% of 32 participants)
    • The MRD kinetics varied in different subgroups, with undetectable MRD rates declining in patients with unmutated IGHV from 60% at 3 months to 36% at 27 months after the end of treatment. Whereas, in patients with mutated IGHV, undetectable MRD rates remained stable in this period (changing from 41% to 44% over this period)
  • CR/CRi was 43% vs 12% in the ibrutinib + venetoclax arm and chlorambucil-obinutuzumab arm, respectively.
    • CR/CRi at 36 months was 93% in the ibrutinib + venetoclax arm vs 60% in the chlorambucil-obinutuzumab arm.
  • Patients in the ibrutinib + venetoclax arm, maintained lymph node clearance, regardless of IGHV mutation or MRD status.
  • 8 vs 41 patients (p < 0.0001) required second-line treatment in the ibrutinib + venetoclax arm and chlorambucil + obinutuzumab arm, respectively.
  • OS was significantly higher for patients in the ibrutinib + venetoclax vs chlorambucil + obinutuzumab arm (hazard ratio of 0.487; p = 0.021).
    • The estimated 42-month OS was 87.5% vs 77.6%, respectively.

Figure 2. 42-month PFS in ibrutinib + venetoclax arm vs chlorambucil + obinutuzumab arm* 

PFS, progression-free survival.

*Adapted from Niemann et al.1 

Safety

  • There were a greater number of deaths reported in the chlorambucil + obinutuzumab arm vs ibrutinib + venetoclax arm, 30 deaths vs 15 deaths, respectively.
  • In the ibrutinib + venetoclax arm, deaths were due to progression (n = 1); treatment-emergent adverse events including cardiac failure, pneumonia, and sinus node dysfunction (n = 7); occurred in remission (n = 6); and occurred during subsequent therapy (n = 1)
  • In the chlorambucil + obinutuzumab arm, deaths were due to progressive disease (n = 1); treatment-emergent adverse events including pneumonia (n = 2); occurred in remission (n = 6); occurred after disease progression but prior to subsequent therapy (n = 13); and occurred during subsequent therapy (n = 8).
  • There were more infection-related deaths reported in the chlorambucil + obinutuzumab arm compared with ibrutinib + venetoclax arm, 11 vs 4 deaths, respectively.
  • A total of 11 patients in the ibrutinib + venetoclax arm and 14 patients in the chlorambucil + obinutuzumab arm experienced a secondary malignancy at longer follow-up.
  • In the chlorambucil + obinutuzumab arm, one patient experienced a serious adverse event of myelodysplastic syndrome.

Conclusion

The 4-year follow-up data of the GLOW trial demonstrated that fixed-duration ibrutinib + venetoclax continues to significantly improve PFS and achieve an OS advantage compared with chlorambucil + obinutuzumab in patients with previously untreated CLL. The findings support the clinical use of this combination regimen as a first-line treatment option in patients with CLL.

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.

  1. Niemann CU, Munir T, Moreno C, et al. Fixed-duration ibrutinib–venetoclax vs chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomized, phase 3 trial. Lancet Oncol. 2023;24(12):1423-1433. DOI: 1016/S1470-2045(23)00452-7

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
55 votes - 65 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox